Madrigal Pharmaceuticals, Inc. (FRA:YDO1)
Germany
· Delayed Price · Currency is EUR 494.20
-10.60 (-2.10%)
At close: Dec 5, 2025
Madrigal Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 295.69 | 100.02 | 99.92 | 331.55 | 36.27 | 54 | Upgrade
|
| Short-Term Investments | 814.06 | 826.23 | 534.22 | 27.23 | 234.08 | 230.15 | Upgrade
|
| Cash & Short-Term Investments | 1,110 | 926.25 | 634.13 | 358.77 | 270.35 | 284.15 | Upgrade
|
| Cash Growth | 11.13% | 46.07% | 76.75% | 32.71% | -4.86% | -35.28% | Upgrade
|
| Accounts Receivable | 113.29 | 53.82 | - | - | - | - | Upgrade
|
| Receivables | 113.29 | 53.82 | - | - | - | - | Upgrade
|
| Inventory | 69.32 | 34.07 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 49.33 | 13.79 | 3.15 | 2.6 | 1.34 | 1.01 | Upgrade
|
| Restricted Cash | 5 | 5 | - | - | - | - | Upgrade
|
| Total Current Assets | 1,347 | 1,033 | 637.28 | 361.37 | 271.68 | 285.16 | Upgrade
|
| Property, Plant & Equipment | 8.3 | 4.59 | 3.27 | 1.2 | 1.65 | 1.83 | Upgrade
|
| Other Intangible Assets | 7.48 | 4.73 | - | - | - | - | Upgrade
|
| Total Assets | 1,362 | 1,042 | 640.55 | 362.57 | 273.33 | 287 | Upgrade
|
| Accounts Payable | 44.94 | 43.6 | 28.04 | 23.83 | 21.38 | 1.02 | Upgrade
|
| Accrued Expenses | 345.38 | 124.7 | 89.98 | 91.46 | 55.05 | 45.22 | Upgrade
|
| Current Portion of Leases | 1.08 | 0.98 | 0.53 | 0.6 | 0.41 | 0.32 | Upgrade
|
| Total Current Liabilities | 391.41 | 169.28 | 118.55 | 115.89 | 76.84 | 46.56 | Upgrade
|
| Long-Term Debt | 339.75 | 117.57 | 115.48 | 49.29 | - | - | Upgrade
|
| Long-Term Leases | 5.57 | 1.02 | 1.19 | - | 0.39 | 0.47 | Upgrade
|
| Total Liabilities | 736.73 | 287.86 | 235.21 | 165.18 | 77.23 | 47.03 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 2,657 | 2,556 | 1,741 | 1,160 | 863.5 | 665.39 | Upgrade
|
| Retained Earnings | -2,032 | -1,802 | -1,336 | -962.66 | -667.31 | -425.46 | Upgrade
|
| Comprehensive Income & Other | 1.07 | 0.47 | 0.47 | -0.03 | -0.08 | 0.05 | Upgrade
|
| Shareholders' Equity | 625.73 | 754.38 | 405.33 | 197.39 | 196.11 | 239.97 | Upgrade
|
| Total Liabilities & Equity | 1,362 | 1,042 | 640.55 | 362.57 | 273.33 | 287 | Upgrade
|
| Total Debt | 346.4 | 119.57 | 117.19 | 49.89 | 0.8 | 0.79 | Upgrade
|
| Net Cash (Debt) | 763.35 | 806.68 | 516.94 | 308.88 | 269.55 | 283.36 | Upgrade
|
| Net Cash Growth | -13.21% | 56.05% | 67.36% | 14.59% | -4.88% | -35.36% | Upgrade
|
| Net Cash Per Share | 34.42 | 37.92 | 27.66 | 18.02 | 16.30 | 18.34 | Upgrade
|
| Filing Date Shares Outstanding | 22.71 | 22.08 | 19.9 | 18.14 | 17.1 | 16.02 | Upgrade
|
| Total Common Shares Outstanding | 22.7 | 22 | 19.88 | 18.1 | 17.1 | 15.51 | Upgrade
|
| Working Capital | 955.27 | 863.65 | 518.73 | 245.48 | 194.85 | 238.61 | Upgrade
|
| Book Value Per Share | 27.56 | 34.28 | 20.39 | 10.90 | 11.47 | 15.47 | Upgrade
|
| Tangible Book Value | 618.26 | 749.65 | 405.33 | 197.39 | 196.11 | 239.97 | Upgrade
|
| Tangible Book Value Per Share | 27.23 | 34.07 | 20.39 | 10.90 | 11.47 | 15.47 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.